Embryonal tumor with multilayered rosettes
Citation, DOI, disclosures and article data
At the time the article was created Dylan Kurda had no recorded disclosures.View Dylan Kurda's current disclosures
Embryonal tumors with multilayered rosettes (ETMR) are rare small round blue cell tumor of the central nervous system. They are one of the most aggressive brain tumors usually encountered in children and are WHO grade 4 tumors.
Previously embryonal tumors with multilayered rosettes (ETMR) were known as embryonal tumor with abundant neuropil and true rosettes (ETANTR). This term was, however, removed from the 2016 update to WHO classification of CNS tumors in favor of embryonal tumors with multilayered rosettes (ETMR) which incorporates not only ETANTR but also ependymoblastoma and primitive neuroectodermal tumor of the central nervous system (CNS PNET), which have also been removed 6.
The terminological changes have resulted from the presence of amplification of the C19MC microRNA cluster on chromosome 19 in both CNS PNET and ETANTR, suggesting that these are the one entity with variable growth pattern 6. Similarly, medulloepithelioma no longer appears as a distinct entity in the 5th Edition (2021) of WHO classification of CNS tumors, and is stated to be "not recommended" terminology 7.
Embryonal tumor with multilayered rosettes occurs in children aged 4 years and under, mostly in children under 2 years, and is more common in girls, unlike the other CNS embryonal tumors, in which boys are equally or more commonly affected 7.
The clinical features are determined by the location and extent of the tumor. Most are supratentorial in location, a few are infratentorial, and they are very rarely encountered in the spinal cord.
Increased intracranial pressure, seizures, hemiparesis, cerebellar signs, cranial nerve palsies, and other neurologic deficits have all been reported.
Embryonal tumors with multilayered rosettes demonstrate one of three histological patterns:
embryonal tumor with abundant neuropil and true rosettes
Typically these tumors are characterized by undifferentiated neuroepithelial cells resembling those of classic CNS PNET (historical), abundant well-differentiated neuropil, and ependymoblastic rosettes scattered throughout paucicellular regions of neoplastic neuropil. It has very characteristic ependymoblastic rosettes in both highly cellular as well as acellular areas.
When they have an ependymoblastoma pattern, they lack ganglion cells and a neuropil-like matrix.
Recently amplification of the C19MC region on chromosome 19 (19q13.42) has been identified as characteristic of these tumors, present in approximately 90% of cases 7.
If C19MC amplification is absent then these tumors are known as ETMR-NOS even if other mutations (e.g. DICER1) are identified 6,7.
The tumor appears as a large, demarcated, solid mass featuring patchy or no contrast enhancement, with surrounding edema, often with significant mass effect. A minority of the reported cases have shown cystic components and microcalcifications.
T1: decreased intensity
T2: increased intensity
T1 C+ (Gd): patchy or no contrast enhancement
Following maximal surgical resection, patients can be staged according to the extent of spread within and outside of the central nervous system 7,8.
M0: no evidence of subarachnoid or hematogenous metastasis
M1: microscopic tumor cells found in the cerebrospinal fluid
M2: gross nodular seeding demonstrated in the cerebellar/cerebral subarachnoid space or in the third or lateral ventricles
M3: gross nodular seeding in the spinal subarachnoid space
M4: metastasis outside the central nervous system
Treatment and prognosis
Current treatment options for ETMR include surgical resection, systemic chemotherapy and craniospinal radiation (when appropriate).
Unfortunately, the prognosis is dismal, with most recent articles reporting ~75% of cases have died within the median survival of 9 months.
The differential diagnosis varies according to the location of the tumor. The general imaging differential for the brainstem and infratentorial embryonal tumors with multilayered rosettes include:
- 1. Ferri Niguez B, Martínez-Lage J, Almagro M et al. Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR): A New Distinctive Variety of Pediatric PNET: A Case-Based Update. Childs Nerv Syst. 2010;26(8):1003-8. doi:10.1007/s00381-010-1179-x - Pubmed
- 2. Gessi M, Giangaspero F, Lauriola L et al. Embryonal Tumors with Abundant Neuropil and True Rosettes: A Distinctive CNS Primitive Neuroectodermal Tumor. Am J Surg Pathol. 2009;33(2):211-7. doi:10.1097/PAS.0b013e318186235b - Pubmed
- 3. Biegel J, Allen C, Kawasaki K, Shimizu N, Budarf M, Bell C. Narrowing the Critical Region for a Rhabdoid Tumor Locus in 22q11. Genes Chromosomes Cancer. 1996;16(2):94-105. doi:10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y - Pubmed
- 4. Adamek D, Sofowora K, Cwiklinska M, Herman-Sucharska I, Kwiatkowski S. Embryonal Tumor with Abundant Neuropil and True Rosettes: An Autopsy Case-Based Update and Review of the Literature. Childs Nerv Syst. 2013;29(5):849-54. doi:10.1007/s00381-013-2037-4 - Pubmed
- 5. Nowak J, Seidel C, Pietsch T et al. Ependymoblastoma of the Brainstem: MRI Findings and Differential Diagnosis. Pediatr Blood Cancer. 2014;61(6):1132-4. doi:10.1002/pbc.24915 - Pubmed
- 6. Louis D, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol. 2016;131(6):803-20. doi:10.1007/s00401-016-1545-1 - Pubmed
- 7. Korshunov A, Wesseling PN, Fuller G, Huang AG, Haberler C, Embryonal tumour with multilayered rosettes. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). https://publications.iarc.fr/601
- 8. Chang C, Housepian E, Herbert C. An Operative Staging System and a Megavoltage Radiotherapeutic Technic for Cerebellar Medulloblastomas. Radiology. 1969;93(6):1351-9. doi:10.1148/93.6.1351 - Pubmed